While cytokine-targeted therapies have significantly transformed the treatment landscape of inflammatory bowel disease (IBD), a substantial proportion of patients remain refractory or lose responsiveness over time. Moreover, cytokine blockade alone may be insufficient to control the highly complex and heterogeneous immune dysregulation that characterizes intestinal inflammation. This has prompted the development of alternative biologic and small-molecule therapies targeting non-cytokine pathways implicated in intestinal inflammation, acting at distinct regulatory levels including immune cell trafficking, intracellular signalling, and lymphocyte recirculation. Here, we review emerging and approved non–cytokine-targeted therapies in IBD, focusing on three major mechanistic categories: anti-integrin agents (vedolizumab, natalizumab, etrolizumab) that selectively block leukocyte trafficking to the intestinal mucosa; Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway inhibitors (tofacitinib, upadacitinib, filgotinib) that interrupt multiple cytokine-mediated intracellular signalling cascades; and sphingosine-1-phosphate (S1P) receptor modulators (ozanimod, etrasimod) that sequester lymphocytes within lymphoid organs by functionally antagonizing S1P1 receptors. For each therapeutic class, we summarize the mechanistic rationale, clinical efficacy, safety profiles, and positioning within current treatment algorithms. Non-cytokine-based therapies represent a critical advance in the personalized management of IBD. By targeting complementary immunological mechanisms beyond cytokine inhibition, they offer new therapeutic options for patients with treatment-refractory disease and expand the arsenal for combination strategies. Furthermore, they highlight the need for precision medicine approaches guided by immune phenotyping, pharmacokinetic monitoring, and biomarker development to optimize therapeutic selection and improve long-term outcomes.